- Technology and Data
- Front End Sales and Marketing
- Allergy
- HIV
- Women's Health
- Migraine
- Compounding
- Continuous Glucose Monitoring
- Mental Health Awareness
- Veterinary Pharmacy
- CBD
- Infectious Disease
- Eye Health
- Digestive Health
- Biosimilars
- Influenza
- Shingles
- COPD Management
- Pediatrics
- Generics
- Pain Management
- COVID-19
- Immunization
- Oncology
- Anticoagulants
- Autoimmune Diseases
- Dermatology
- Diabetes
- Respiratory
- Heart Health
- Cardiovascular Clinical Consult
Hospira unveils plans to acquire injectable company
Hospital products giant Hospira Inc., based in Lake Forrest, Ill., announced that it will acquire Australia?s Mayne Pharma Limited for $2 billion.
Hospital products giant Hospira Inc., based in Lake Forrest, Ill., announced that it will acquire Australia’s Mayne Pharma Limited for $2 billion. Executives on both sides believe that the Hospira/Mayne combo will be a good fit strategically and establish Hospira as the worldwide leader in generic injectable pharmaceuticals. Mayne Pharma is a market leader in Europe and Australia and has a significant presence in Canada. Hospira expects the alliance to strengthen its global reach. Hospira, the hospital products division of Abbott Laboratories, is a global specialty pharmaceutical and medication delivery company.
To see more Hot off the Press news articles, click here.
To go to the Drug Topics homepage, click here.
